Safety and Efficacy of First-Line Treatments for Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Indirect Comparison

被引:13
作者
Zheng, Haofeng [1 ]
Chen, Jialiang [1 ]
Qiu, Wenhan [1 ]
Lin, Sijie [1 ]
Chen, Yanxiong [1 ]
Liang, Guancan [1 ]
Fang, Youqiang [1 ]
机构
[1] Sun Yat Sen Univ, Dept Urol, Affiliated Hosp 3, Guangzhou 510630, Guangdong, Peoples R China
关键词
ABIRATERONE ACETATE; SIPULEUCEL-T; PLUS PREDNISONE; DOUBLE-BLIND; PHASE-III; ENZALUTAMIDE; DOCETAXEL; IMMUNOTHERAPY; SURVIVAL; THERAPY;
D O I
10.1155/2017/3941217
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Recently, several drugs have been introduced for the first-line treatment of chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC), but few studies have compared treatment outcomes directly. This indirect comparison among 10 clinical trials (n = 4870 patients) retrieved from PubMed, Web of Science, Cochrane Collaboration, and ClinicalTrails.gov was performed to assess the safety and efficacy of docetaxel, cabazitaxel, abiraterone, enzalutamide, and sipuleucel-T for the initial treatment of mCRPC. No significant differences in primary outcome (overall survival) were found among initial treatments. However, docetaxel had the highest probability (37.53%) of being the most effective, but at the cost of more adverse events, while enzalutamide was associated with the best secondary outcomes (prostate-specific antigen response, progression-free survival, quality of life, and adverse event profile). Thus, docetaxel is recommended as the first agent used for the chemotherapy of mCRPC, while enzalutamide is recommended as the first nonchemotherapy treatment. Additional clinical trials are needed to confirm these findings and establish the optimal order for multidrug treatment of mCRPC.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Abiraterone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: a systematic review of "real-life' studies
    Marchioni, Michele
    Sountoulides, Petros
    Bada, Maida
    Rapisarda, Sebastiano
    De Nunzio, Cosimo
    Tamburro, Fabiola Raffaella
    Schips, Luigi
    Cindolo, Luca
    THERAPEUTIC ADVANCES IN UROLOGY, 2018, 10 (10) : 305 - 315
  • [2] US Food and Drug Administration Approval Summary: Enzalutamide for the Treatment of Patients With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
    Ning, Yang-Min
    Brave, Michael
    Maher, V. Ellen
    Zhang, Lijun
    Tang, Shenghui
    Sridhara, Rajeshwari
    Kim, Geoffrey
    Ibrahim, Amna
    Pazdur, Richard
    ONCOLOGIST, 2015, 20 (08) : 960 - 966
  • [3] First-line non-cytotoxic therapy in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: a systematic review of 10 randomised clinical trials
    Poorthuis, Michiel H. F.
    Vernooij, Robin W. M.
    van Moorselaar, R. Jeroen A.
    de Reijke, Theo M.
    BJU INTERNATIONAL, 2017, 119 (06) : 831 - 845
  • [4] Systematic Review and Network Meta-Analysis of Treatments for Chemotherapy-Naive Patients with Asymptomatic/Mildly Symptomatic Metastatic Castration-Resistant Prostate Cancer
    McCool, Rachael
    Fleetwood, Kelly
    Glanville, Julie
    Arber, Mick
    Goodall, Howard
    Naidoo, Shevani
    VALUE IN HEALTH, 2018, 21 (10) : 1259 - 1268
  • [5] Taxane chemotherapy vs antiandrogen agents as first-line therapy for metastatic castration-resistant prostate cancer
    Sonpavde, Guru
    Huang, Ahong
    Wang, Li
    Baser, Onur
    Miao, Raymond
    BJU INTERNATIONAL, 2018, 121 (06) : 871 - 879
  • [6] Budget Impact of Enzalutamide for Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
    Bui, Cat N.
    O'Day, Ken
    Flanders, Scott
    Oestreicher, Nina
    Francis, Peter
    Posta, Linda
    Popelar, Breanna
    Tang, Hong
    Balk, Mark
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2016, 22 (02) : 163 - U171
  • [7] Enzalutamide: A Review of Its Use in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer
    Keating, Gillian M.
    DRUGS & AGING, 2015, 32 (03) : 243 - 249
  • [8] Management of metastatic castration-resistant prostate cancer after first-line docetaxel
    Harrington, J. A.
    Jones, R. J.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 (14) : 2133 - 2142
  • [9] Comparative therapeutic efficacy and safety of first-line and second-line therapies for metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
    Jiang, Bohao
    Wang, Benqiao
    Chen, Yiming
    Chen, Yaang
    Li, Bohan
    Bi, Jianbin
    ECLINICALMEDICINE, 2025, 81
  • [10] Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter "real life" study
    Cindolo, Luca
    Natoli, Clara
    De Nunzio, Cosimo
    De Tursi, Michele
    Valeriani, Maurizio
    Giacinti, Silvana
    Micali, Salvatore
    Rizzo, Mino
    Bianchi, Giampaolo
    Martorana, Eugenio
    Scarcia, Marcello
    Ludovico, Giuseppe Mario
    Bove, Pierluigi
    Laudisi, Anastasia
    Selvaggio, Oscar
    Carrieri, Giuseppe
    Bada, Maida
    Castellan, Pietro
    Boccasile, Stefano
    Ditonno, Pasquale
    Chiodini, Paolo
    Verze, Paolo
    Mirone, Vincenzo
    Schips, Luigi
    BMC CANCER, 2017, 17